Citi analyst Yigal Nochomovitz maintained a Sell rating on Sarepta Therapeutics today and set a price target of $14.00. The company’s shares opened today at $18.14.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nochomovitz covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Sarepta Therapeutics, and Krystal Biotech. According to TipRanks, Nochomovitz has an average return of 5.2% and a 40.00% success rate on recommended stocks.
In addition to Citi, Sarepta Therapeutics also received a Sell from Needham’s Gil Blum in a report issued yesterday. However, on the same day, BMO Capital reiterated a Hold rating on Sarepta Therapeutics (NASDAQ: SRPT).
The company has a one-year high of $144.22 and a one-year low of $10.42. Currently, Sarepta Therapeutics has an average volume of 11.38M.
Read More on SRPT:
- Cautious Outlook for Sarepta Therapeutics Amid Uncertain Demand and Regulatory Challenges
- Sarepta Therapeutics: Hold Rating Amid Revenue Decline and Regulatory Challenges
- Cautious Outlook on Sarepta Therapeutics Amid Financial Strain and ELEVIDYS Challenges
- Sarepta price target raised to $50 from $48 at Wells Fargo
- Sell Rating Issued for Sarepta Therapeutics Amid Uncertain Revenue Prospects and High Future Expenses